---
title: "Molbio Diagnostics (MOLBIO) Share Price, Financials & Research"
symbol: "MOLBIO"
company: "Molbio Diagnostics Ltd"
canonical: "https://tapetide.com/stocks/MOLBIO"
isin: "INE869T01028"
nse_symbol: "MOLBIO"
bse_code: "544866"
sector: "Healthcare"
industry: "Healthcare Equipment & Supplies"
generated_at: "2026-11-05T01:41:08.629Z"
---

# Molbio Diagnostics (MOLBIO)

Canonical page: https://tapetide.com/stocks/MOLBIO

## Key Facts

- **Price:** ₹1,381.80 as of 4 Nov 2026, 15:57 IST
- **P/E (TTM):** 123.38 as of 4 Nov 2026
- **Revenue, Jun 2026 quarter:** ₹399.4 Cr, against ₹95.3 Cr in Jun 2025 (+319.10% year on year)
- **Net profit, Jun 2026 quarter:** ₹57 Cr, against -₹13 Cr in Jun 2025
- **Promoter holding:** 41.29% in Sep 2026

## Company

- **NSE symbol:** MOLBIO
- **BSE code:** 544866
- **ISIN:** INE869T01028
- **Macro sector:** Healthcare
- **Sector:** Healthcare
- **Industry:** Healthcare Equipment & Supplies
- **Basic industry:** Medical Equipment & Supplies
- **In the F&O segment:** No

## Latest Price

- **Price:** ₹1,381.80
- **Change:** No trade today
- **Previous Close:** ₹1,381.80
- **As of:** 4 Nov 2026, 15:57 IST

## Key Fundamentals

Price-based figures as of 4 Nov 2026, 15:57 IST · TTM.

- **ROCE:** 18.00%
- **Debt to Equity:** 0.31
- **EPS (TTM):** ₹11.20
- **Book Value:** ₹118.84
- **P/E (TTM):** 123.38
- **P/B:** 11.63
- **ROE:** 13.80%
- **Dividend Yield:** 0.00%
- **EBITDA:** ₹331 Cr
- **52W High:** ₹1,686.80
- **52W Low:** ₹926.35

## Key Insights

### Strengths

- Company's working capital requirements have reduced from 179 days to 143 days

## Technical Indicators

As of 4 Nov 2026.

| Group | Signal | Bearish | Neutral | Bullish |
| --- | --- | ---: | ---: | ---: |
| Overall | Bullish | 2 | 10 | 7 |
| Oscillators | Bearish | 2 | 6 | 1 |
| Moving Averages | Strong Bullish | 0 | 4 | 6 |

### Oscillators: Bearish

| Name | Value | Signal |
| --- | ---: | --- |
| RSI (14) | 53.97 | Neutral |
| MACD (12,26,9) | 0.23 | Bearish |
| Stochastic (14,3,3) | 27.04 | Neutral |
| ADX (14) | 26.44 | Bullish |
| Williams %R (14) | -65.57 | Neutral |
| ATR (14) | 89.69 | Neutral |
| ROC (12) | -12.23 | Bearish |
| Stoch RSI (14) | 48.82 | Neutral |
| UO (7,14,28) | 48.20 | Neutral |

### Moving Averages: Strong Bullish

| Name | Value | Signal |
| --- | ---: | --- |
| SMA (10) | 1,297.41 | Bullish |
| EMA (10) | 1,334.02 | Bullish |
| SMA (20) | 1,378.65 | Bullish |
| EMA (20) | 1,341.38 | Bullish |
| SMA (50) | 1,306.31 | Bullish |
| EMA (50) | 1,288.71 | Bullish |
| SMA (100) | — | Neutral |
| EMA (100) | — | Neutral |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Pivot Points

| Level | Classic | Fibonacci | Camarilla |
| --- | ---: | ---: | ---: |
| R3 | 1,458.54 | 1,425.27 | 1,396.93 |
| R2 | 1,425.27 | 1,404.26 | 1,391.88 |
| R1 | 1,403.54 | 1,391.28 | 1,386.84 |
| PP | 1,370.27 | 1,370.27 | 1,370.27 |
| S1 | 1,348.54 | 1,349.26 | 1,376.76 |
| S2 | 1,315.27 | 1,336.28 | 1,371.72 |
| S3 | 1,293.54 | 1,315.27 | 1,366.68 |

## Analyst Rating

Based on 1 analyst. 1 of 1 analyst rates Buy, 0 Hold, 0 Sell. As of 4 Nov 2026.

| Rating | Analysts | Share |
| --- | ---: | ---: |
| Buy | 1 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

## Growth Rate

Growth computed from the financial statements below. A window with no rate gives the reason instead of a figure.

| Metric | Window | Growth | What it compares |
| --- | --- | ---: | --- |
| Revenue | 5Y | 0.65% | compounded annual rate, Mar 2021 to Mar 2026 |
| Revenue | 3Y | 58.94% | compounded annual rate, Mar 2023 to Mar 2026 |
| Revenue | 1Y | 35.22% | fiscal year to Mar 2026 vs the year to Mar 2025 |
| Net profit | 5Y | -18.77% | compounded annual rate, Mar 2021 to Mar 2026 |
| Net profit | 3Y | 108% | compounded annual rate, Mar 2023 to Mar 2026 |
| Net profit | 1Y | 3.57% | fiscal year to Mar 2026 vs the year to Mar 2025 |
| Operating cash flow | 5Y | Turned negative | compounded annual rate, Mar 2021 to Mar 2026: ₹344 Cr to -₹38.00 Cr. A cash inflow at the start and an outflow at the end. |
| Operating cash flow | 3Y | Turned negative | compounded annual rate, Mar 2023 to Mar 2026: ₹68.00 Cr to -₹38.00 Cr. A cash inflow at the start and an outflow at the end. |
| Operating cash flow | 1Y | Turned negative | fiscal year to Mar 2026 vs the year to Mar 2025: ₹249 Cr to -₹38.00 Cr. A cash inflow at the start and an outflow at the end. |
| Operating margin | 5Y | -27.62 pp | compounded annual rate, Mar 2021 to Mar 2026 |
| Operating margin | 3Y | +6.96 pp | compounded annual rate, Mar 2023 to Mar 2026 |
| Operating margin | 1Y | -4.08 pp | fiscal year to Mar 2026 vs the year to Mar 2025 |

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

## Analyst Forecasts

Consensus of analyst estimates, as of 4 Nov 2026. Low and High are the range of the estimates, not a confidence interval.

### EBITDA (annual)

FY27 consensus: ₹478 Cr (+44.6% vs ₹331 Cr in FY26).

| Period | Mean | Low | High |
| --- | ---: | ---: | ---: |
| FY27 | ₹478 Cr | ₹478 Cr | ₹478 Cr |
| FY28 | ₹674 Cr | ₹674 Cr | ₹674 Cr |

### EPS (annual)

FY27 consensus: ₹25.20 (+70.6% vs ₹14.77 in FY26).

| Period | Mean | Low | High |
| --- | ---: | ---: | ---: |
| FY27 | ₹25.20 | ₹25.20 | ₹25.20 |
| FY28 | ₹39.90 | ₹39.90 | ₹39.90 |

### Net Income (annual)

FY27 consensus: ₹284 Cr (+73.1% vs ₹164 Cr in FY26).

| Period | Mean | Low | High |
| --- | ---: | ---: | ---: |
| FY27 | ₹284 Cr | ₹284 Cr | ₹284 Cr |
| FY28 | ₹449 Cr | ₹449 Cr | ₹449 Cr |

### Price (quarterly)

Mar 2027 consensus: ₹1,800.00 (+37.5% vs ₹1,308.90 in Sep 2026).

| Period | Mean | Low | High |
| --- | ---: | ---: | ---: |
| Mar 2027 | ₹1,800.00 | ₹1,800.00 | ₹1,800.00 |

### Revenue (annual)

FY27 consensus: ₹1,831 Cr (+25.8% vs ₹1,455 Cr in FY26).

| Period | Mean | Low | High |
| --- | ---: | ---: | ---: |
| FY27 | ₹1,831 Cr | ₹1,831 Cr | ₹1,831 Cr |
| FY28 | ₹2,286 Cr | ₹2,286 Cr | ₹2,286 Cr |

### ROE (annual)

FY27 consensus: 21.7% (+9.2 pp vs 12.5% in FY26).

| Period | Mean | Low | High |
| --- | ---: | ---: | ---: |
| FY27 | 21.7% | 21.7% | 21.7% |
| FY28 | 26.8% | 26.8% | 26.8% |

## AI Analysis — Bull vs Bear

AI-generated opinion, based on fundamentals. Figures as of 4 Nov 2026. Not investment advice, and not a recommendation to buy, sell or hold. Statements that rate the stock or set a price target are left out of this copy.

- **Risk (AI assessment):** High

Molbio Diagnostics trades at a PE of 123.38x as of 2026-11-04, reflecting premium valuation for a healthcare diagnostics company with a market cap of ₹15,606.95 crore. The company has delivered strong 3-year compounded sales growth of 59% and profit growth of 111%, though longer-term 5-year trends show flat sales growth at 1% and negative profit growth of -19%, highlighting the cyclical nature of its earnings trajectory.

### Bull Case

- 3-year compounded profit growth of 111% demonstrates a strong earnings recovery cycle, significantly outpacing most diagnostics peers
- 3-year compounded sales growth of 59% indicates robust revenue momentum and expanding market penetration
- TTM sales growth of 35% shows the top-line acceleration is continuing into recent quarters
- Low debt-to-equity ratio of 0.31 as of 2026-11-04 reflects a conservatively financed balance sheet with limited leverage risk
- ROCE of 16.63% as of 2026-11-04 indicates the company is generating meaningful returns on total capital deployed
- Working capital requirements have improved from 179 days to 143 days, freeing up cash and improving operational efficiency
- The stock has rallied roughly 49% from its 52-week low of ₹926.35 to ₹1,381.80 as of 2026-11-04, reflecting improving investor sentiment
- 3-year average ROE of 15% and 5-year average ROE of 16% suggest the company has maintained reasonable shareholder returns over multiple cycles

### Bear Case

- Price-to-book ratio of 11.63x as of 2026-11-04 implies the market is pricing in substantial future growth that may already be discounted
- 5-year compounded profit growth of -19% reveals that current earnings remain below levels achieved five years ago, underscoring earnings volatility
- 5-year compounded sales growth of just 1% indicates that the recent revenue surge may be a recovery rather than structural growth
- TTM profit growth of only 1% suggests earnings expansion has stalled even as sales grew 35% in the same period, pointing to margin compression
- Zero dividend yield as of 2026-11-04 means shareholders receive no income return and are entirely dependent on capital appreciation
- Last year ROE of 14% trails the 5-year average of 16%, indicating a declining trend in return on equity
- The stock trades about 18% below its 52-week high of ₹1,686.80, suggesting potential resistance at higher levels

This is AI-generated analysis, not financial advice. Do your own due diligence.

## AI News Digest

AI-generated summary of recent news, generated 4 Nov 2026. Not investment advice, and not a recommendation to buy, sell or hold. Statements that rate the stock or set a price target are left out of this copy.

**TL;DR:** Molbio Diagnostics is delivering strong top-line growth with FY26 revenue up 41.7% and a dramatic Q1FY27 ramp, driven by rapidly scaling test-kit volumes on its proprietary Truenat platform. The recurring consumables model (74–75% of product revenue) and large untapped private-sector opportunity provide visible growth levers. Key risks include a stretched valuation at ~76–90x P/E, dependence on government tenders causing quarterly lumpiness, and still-modest capacity utilization. If the company executes on its FY27 margin and growth targets while expanding its private-sector and international footprint, the fundamental trend remains firmly positive despite near-term stock volatility.

### Headwinds

- **High valuation, P/E near 90x** (Oct 22): Stock trades at a P/E of roughly 76–90x at around ₹1,322–₹1,442 per share, with no meaningful historical valuation trend available given its recent listing.
- **Government tender dependence risk** (Oct 22): Heavy reliance on government healthcare tenders and institutional procurement can cause lumpy, uneven quarterly results due to tender awards, approvals, and shipment schedules.
- **Stock fell ~7.9% in a day** (Oct 22): Shares traded at ₹1,322 on Oct 21, down 7.86% from the previous close of ₹1,434.80.
- **Capacity utilization still low** (Oct 22): FY26 capacity utilization stood at only 58.25% for test kits and 42.30% for Truenat devices against annual capacity of 39 million kits and 5,400 devices.

### Positives

- **FY26 revenue up 41.7% YoY** (Oct 22): Revenue rose 41.7% YoY to ₹1,446 crore in FY26 while net profit increased 14.9% to ₹164 crore, with EBITDA margin improving to 22.6%.
- **Q1FY27 revenue surges 4x** (Oct 22): Q1FY27 revenue jumped to ₹408.4 crore from ₹99.7 crore a year earlier, with EBITDA swinging to ₹103.7 crore from a loss of ₹14.5 crore in Q1FY26.
- **Test-kit volumes 41% CAGR** (Oct 22): Test-kit volumes grew at a 41% CAGR from 8.8 million units in FY24 to 17.6 million in FY26, with Q1FY27 alone reaching 6.2 million units versus 0.8 million a year ago.
- **Massive private-sector runway** (Oct 22): Only about 1,400 of an estimated 17,000 private healthcare facilities in India have molecular diagnostic capability, offering large untapped expansion potential alongside 90%+ public-sector installed base share.
- **Diversification via acquisitions** (Oct 22): Acquisition of Prognosys Medical Systems (portable X-ray, targeting ₹390 crore revenue by FY29 at 36% CAGR) and 60% stake in OptraScan (AI pathology, ₹290 crore revenue target by FY29) broaden the portfolio.
- **Revenue can double, low capex** (Oct 22): Management indicates revenue could potentially double from current levels with limited additional capital spending, targeting ~25% revenue growth and 24–25% EBITDA margin for FY27.
- **Global Truenat platform scale** (Oct 22): Over 12,500 Truenat devices installed across 90+ countries with 40 million+ tests conducted; 43 commercial assays covering 30 diseases and 34 more in development.

### Neutral

- **Kotak MF crosses 5% stake** (Oct 13): Kotak Mahindra Mutual Fund acquired 570,000 shares, taking its holding to 5.4834% under SAST regulations.

## Financial Statements

### Quarterly Results

Figures in ₹ crore unless the row name gives another unit.

| Item | Jun 2025 | Mar 2026 | Jun 2026 |
| --- | ---: | ---: | ---: |
| Sales | 95 | 439 | 399 |
| Expenses | 105 | 332 | 308 |
| Operating Profit | -10 | 107 | 92 |
| OPM % | -10% | 24% | 23% |
| Other Income | 1 | 3 | 1 |
| Interest | 2 | 9 | 9 |
| Depreciation | 7 | 10 | 8 |
| Profit before tax | -17 | 91 | 76 |
| Tax % | -23% | 28% | 25% |
| Net Profit | -13 | 66 | 57 |
| EPS in Rs | -5.95 | 5.83 | 5.02 |

### Profit & Loss

Figures in ₹ crore unless the row name gives another unit.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Sales | 1,271 | 776 | 327 | 756 | 971 | 1,313 |
| Expenses | 676 | 457 | 286 | 552 | 746 | 1,061 |
| Operating Profit | 595 | 319 | 40 | 204 | 226 | 252 |
| OPM % | 47% | 41% | 12% | 27% | 23% | 19% |
| Other Income | 1 | 5 | 8 | -21 | -2 | 4 |
| Interest | 35 | 25 | 6 | 8 | 9 | 23 |
| Depreciation | 12 | 42 | 19 | 24 | 26 | 36 |
| Profit before tax | 549 | 258 | 23 | 152 | 188 | 198 |
| Tax % | 25% | 27% | 32% | 27% | 26% | 27% |
| Net Profit | 410 | 187 | 16 | 111 | 140 | 145 |
| EPS in Rs | 2,027 | 833 | 69 | 493 | 62 | 12.83 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |

### Balance Sheet

Figures in ₹ crore unless the row name gives another unit.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 11 |
| Reserves | 333 | 681 | 737 | 848 | 988 | 1,123 |
| Borrowings | 257 | 105 | 57 | 70 | 26 | 346 |
| Other Liabilities | 215 | 85 | 123 | 157 | 291 | 260 |
| Total Liabilities | 806 | 874 | 920 | 1,077 | 1,307 | 1,741 |
| Fixed Assets | 55 | 182 | 189 | 209 | 215 | 257 |
| CWIP | 100 | 0 | 0 | 2 | 18 | 6 |
| Investments | 9 | 9 | 54 | 54 | 95 | 317 |
| Other Assets | 643 | 683 | 676 | 813 | 980 | 1,160 |
| Total Assets | 806 | 874 | 920 | 1,077 | 1,307 | 1,741 |

### Cash Flow

Figures in ₹ crore unless the row name gives another unit.

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash from Operating Activity | 344 | 98 | 68 | 38 | 249 | -38 |
| Cash from Investing Activity | -142 | -87 | -51 | -31 | -98 | -256 |
| Cash from Financing Activity | -192 | -20 | 31 | -24 | -17 | 292 |
| Net Cash Flow | 10 | -9 | 48 | -18 | 133 | -2 |
| Free Cash Flow | 212 | 35 | 55 | 24 | 206 | -74 |
| CFO/OP | 78 | 53 | 251 | 39 | 139 | 6 |

### Ratios

| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Debtor Days | 61 | 113 | 194 | 174 | 86 | 100 |
| Inventory Days | 261 | 402 | 885 | 393 | 395 | 286 |
| Days Payable | 124 | 64 | 201 | 129 | 226 | 130 |
| Cash Conversion Cycle | 198 | 450 | 877 | 438 | 254 | 256 |
| Working Capital Days | 75 | 206 | 479 | 239 | 155 | 143 |
| ROCE % | — | 41% | 4% | 22% | 21% | 18% |

## Shareholding Pattern

### Quarterly Shareholding

Holdings in % of shares; shareholders as a count.

| Holder | Sep 2026 |
| --- | ---: |
| Promoters | 41.29% |
| FIIs | 1.59% |
| DIIs | 19.08% |
| Government | 0.00% |
| Public | 25.00% |
| Others | 13.04% |
| No. of Shareholders | 50,395 |

## Documents

### Concalls

| Month | Call documents |
| --- | --- |
| Sep 2026 | [Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d0065f6b-c9ca-4cb6-ba2c-043630362b96.pdf), [PPT](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc927fc5-ef3e-46b1-bf23-b155d8162fe3.pdf), [Recording](https://www.molbiodiagnostics.com/wp-content/uploads/2026/09/earnings-call-recording-q1-fy27.mp3) |

### Results

| Date | Document |
| --- | --- |
| 5 Sep 2026 | [Outcome Of Board Meeting Held On Saturday September 05 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f41ff2b-3974-4532-b329-5794337b6ce8.pdf) |

### Exchange filings

Latest 12 of 23.

| Date | Document | Category |
| --- | --- | --- |
| 2 Nov 2026 | [Board Meeting Intimation for Approval Of The Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended September 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6f9cca12-c9f3-4a67-bb12-4e8b74e4bddf.pdf) | Intimation |
| 2 Nov 2026 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1826e005-de51-4c7c-a896-391153543551.pdf) | General announcements |
| 19 Oct 2026 | [Clarification On Spurt In Volume Of Shares Of The Company.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=83feae5c-ec0f-4127-b218-4e140435d373.pdf) | General announcements |
| 16 Oct 2026 | [Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3F4BF148_2191_4599_B4FB_6A11318F6019_101308.pdf) | General |
| 13 Oct 2026 | [Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=B9A8CF3A_317F_4570_937A_DE5094DFE17A_102205.pdf) | General |
| 8 Oct 2026 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9e60f5d4-d718-4c5f-a63e-ba279e688196.pdf) | General announcements |
| 1 Oct 2026 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=C1129ED3_93A6_4C1A_8179_1F70C9970166_154027.pdf) | General |
| 1 Oct 2026 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=A81677B6_2AC4_4098_B1DF_FD08973602BE_102051.pdf) | General |
| 28 Sep 2026 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cfe99165-5293-4c7f-a688-45bde35d5bac.pdf) | Intimation |
| 25 Sep 2026 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=E0CF22B0_CEC1_44AD_8A0B_51DF1ECB7BDF_114307.pdf) | General |
| 25 Sep 2026 | [Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3E399B3A_2CE8_44E7_A15D_FC3A4F066E07_131450.pdf) | General |
| 25 Sep 2026 | [Board Meeting Outcome for Re-Appointment Of Cost Auditor Of The Company For FY 2026-27.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d1d3d222-e4be-4929-9ca5-2120a80fe3a7.pdf) | Outcome |

## Frequently Asked Questions about Molbio Diagnostics

### What does Molbio Diagnostics Ltd do?

Molbio Diagnostics is an innovative point- of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases.

### Where is Molbio Diagnostics Ltd (MOLBIO) listed?

Molbio Diagnostics Ltd trades as MOLBIO on the NSE and under code 544866 on the BSE.

### Which sector does Molbio Diagnostics Ltd belong to?

Molbio Diagnostics Ltd is classified under the Healthcare sector, in the Healthcare Equipment & Supplies industry.

### What is the PE ratio of Molbio Diagnostics Ltd?

Molbio Diagnostics Ltd trades at a PE ratio of 123.38 as of 4 Nov 2026, on earnings per share of ₹11.2, against a book value of ₹118.84 per share.

### What is the 52-week high and low of Molbio Diagnostics Ltd?

Over the last 52 weeks Molbio Diagnostics Ltd has traded between ₹926.35 and ₹1,686.8 as of 4 Nov 2026.

### What is the Return on Equity (ROE) of Molbio Diagnostics Ltd?

Molbio Diagnostics Ltd reported a return on equity of 13.80%. Its debt-to-equity ratio is 0.31.

## Company Information

Molbio Diagnostics is an innovative point- of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care. Through its wholly owned subsidiary, Bigtec Labs, Molbio has strong research and development capabilities focused on creating diagnostic platforms for point-of- care (POC) testing. From product development to large-scale deployment, the company aims to improve access to reliable and affordable healthcare for everyone.

- **Website:** https://molbiodiagnostics.com/
- **Listed:** 17 Aug 2026
- **Face Value:** ₹1

---

Negative figures use an ASCII hyphen-minus (-) so they parse as numbers. Amounts are in Indian rupees; "Cr" is crore (10 million). Dates are Indian Standard Time.

Financial statements, shareholding and filings are as reported by the company. Price, volume and 52-week levels are market data. Technical indicators are computed by Tapetide from daily prices. The Tapetide Score is Tapetide’s own analysis. Analyst ratings and forecasts are the published estimates of third-party analysts, not company statements. The AI sections are generated text.

For research and information only, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Generated 5 Nov 2026, 07:11 IST.